United States
SMN ELISA kit
First ready-to-use SMN ELISA kit commercially available for neurodegenerative disease research.
| ADI-900-209 | 96 wells | 475.00 USD |  |
||
- Sensitive - measure as little as 50 pg/mL of SMN
- Quantitative - fully quantitative results surpass semi-quantitative Western blot analysis
- Convenient - ready-to-use liquid color coded reagents and pre-coated 96-well plate
- Time Saving- results from up to 39 samples in duplicate in just 3 hours
The SMN EIA kit is a colorimetric immunometric immunoassay kit with results in 3 hours.
Please mouse over
Product Specification
| Alternative Name: | Survival Motor Neuron |
| Sensitivity: | 50pg/ml (range 50-3200pg/ml) |
| Kit/Set Contains: | Microtiter Plate, Conjugate, Antibody, Assay Buffer 13, Wash Buffer Concentrate, Standard, TMB Substrate, Stop Solution 2, Extraction Reagent 4 |
| Application: | For the quantitative determination of human and mouse SMN in cell lysate samples. |
| Long Term Storage: | -20°C |
| Use/Stability: | Store all components at +4ºC, except Standard at -20ºC. |
| Miscellaneous/General: | The SMN ELISA kit is a complete kit for the quantitative determination of SMN in samples of human and mouse origin. The kit was developed in collaboration with the SMA Foundation (New York, NY). Please read the complete kit insert before performing this assay. Survival Motor Neuron (SMN) is a ~38 kDa protein produced chiefly by the SMN1 gene, located on the telomeric portion of chromosome 5q. A nearly identical centromeric copy of the gene (SMN2) also produces a small amount of full-length SMN protein, but due to a translationally silent C-T transition that results in alternative splicing of the pre-mRNA, most of the resulting SMN is truncated, causing reduced protein stability and lower overall SMN levels. Deletion or mutation of the SMN1 gene results in a reduced level of full-length SMN protein and manifests as a range of neuromuscular phenotypes in humans as the disease spinal muscular atrophy (SMA). SMA is characterized by muscle weakness and atrophy, functional disability and is the most common lethal genetic disease of infants and toddlers. Approximately one in 35 adults is a carrier of the SMN1 mutation. The incidence of SMA is 1 in 6,000 to 1 in 10,000 live births. SMN protein is present in the cell cytoplasm, and also in the nucleus where it is concentrated in “gem” structures associated with Cajal bodies. SMN protein is a constituent of Gemin-containing complexes, and is thought to participate in many aspects of RNA metabolism. SMN complexes have been shown to mediate the assembly of uridine rich small nuclear ribonucleoproteins (snRNPs), which in turn act as critical components of spliceosomes. |
| Background / Technical Information: | Protected by US Patent no. US. 6,080,577. |
Product Toolbox
PRODUCT RESOURCES
Datasheet
Assay Layout Sheet
MSDS
Manual
RELATED PRODUCTS
By catalog section:
By biological activity:
SMN Immunoassay kitPRODUCT SUPPORT
Technical ServiceBulk Quantity Quote
Customer Service
